Skip to content

Study · Animal study (in vivo) · mouse · 2013

2 results

Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.

Liu Z, Jiang M, Kang T, Miao D, Gu G, Song Q, Yao L, Hu Q, Tu Y, Pang Z, Chen H, Jiang X, Gao X, Chen J

Biomaterials27 Feb 2013Cited by 136 (Europe PMC)

PMID23453061 (opens in a new tab)DOI10.1016/j.biomaterials.2013.02.003 (opens in a new tab)PepBankPUB-23453061
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, lactoferrin nanoparticle-delivered NAP showed memory improvement at a lower dose than NAP in unmodified nanoparticles.

    In plain wordsIn mice, NAP in lactoferrin nanoparticles improved memory at a lower dose than NAP in unmodified nanoparticles.

    Peptide
    Davunetide
    Outcome
    IncreaseMemory improvement
    Study

    micen: not reported in source

    mice hippocampus
    Comparator
    NAP in unmodified nanoparticles
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (mice).

    Source sentences

    Summary
    Using a neuroprotective peptide - NAPVSIPQ (NAP) as the model drug, the neuroprotective and memory improvement effect of Lf-NP was observed even at lower dose than that of NP in a Morris water maze experiment
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, lactoferrin nanoparticle-delivered NAP showed a neuroprotective effect at a lower dose than NAP in unmodified nanoparticles.

    In plain wordsIn mice, NAP in lactoferrin nanoparticles showed protection at a lower dose than NAP in unmodified nanoparticles.

    Peptide
    Davunetide
    Outcome
    Direction not reportedNeuroprotection
    Study

    micen: not reported in source

    Comparator
    NAP in unmodified nanoparticles
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (mice).

    Source sentences

    Summary
    Using a neuroprotective peptide - NAPVSIPQ (NAP) as the model drug, the neuroprotective and memory improvement effect of Lf-NP was observed even at lower dose than that of NP in a Morris water maze experiment
    1 context sentence
    Summary · context
    which was also confirmed by the evaluation of acetylcholinesterase, choline acetyltransferase activity and neuronal degeneration in the mice hippocampus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.